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Br ief Definitive Repor t

AAV-mediated expression of anti-tau scFvs decreases tau
accumulation in a mouse model of tauopathy
Christina Ising,* Gilbert Gallardo,* Cheryl E.G. Leyns, Connie H. Wong, Hong Jiang, Floy Stewart,
Lauren J. Koscal, Joseph Roh, Grace O. Robinson, Javier Remolina Serrano, and David M. Holtzman

The Journal of Experimental Medicine

Department of Neurology, Hope Center for Neurological Disorders, Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University,
St. Louis, MO 63110

T auopathies are characterized by the progressive accumulation of hyperphosphorylated, aggregated forms of tau. Our laboratory has previously demonstrated that passive immunization with an anti-tau antibody, HJ8.5, decreased accumulation of
pathological tau in a human P301S tau-expressing transgenic (P301S-tg) mouse model of frontotemporal dementia/tauopathy. To investigate whether the Fc domain of HJ8.5 is required for the therapeutic effect, we engineered single-chain variable
fragments (scFvs) derived from HJ8.5 with variable linker lengths, all specific to human tau. Based on different binding properties, we selected two anti-tau scFvs and tested their efficacy in vivo by adeno-associated virus–mediated gene transfer to
the brain of P301S-tg mice. The scFvs significantly reduced levels of hyperphosphorylated, aggregated tau in brain tissue of
P301S-tg mice, associated with a decrease in detergent-soluble tau species. Interestingly, these mice showed substantial levels
of scFvs in the cerebrospinal fluid without significant effects on total extracellular tau levels. Therefore, our study provides a
novel strategy for anti-tau immunotherapeutics that potentially limits a detrimental proinflammatory response.
INTRODUCTION
Under normal conditions, tau is a highly soluble and natively unfolded microtubule-associated protein (Weingarten
et al., 1975; Witman et al., 1976). However, there are several
neurodegenerative diseases known as tauopathies, including
progressive supranuclear palsy, corticobasal degeneration, certain forms of frontotemporal dementia, chronic traumatic
encephalopathy, and Alzheimer’s disease, in which hyperphosphorylated, insoluble tau accumulates inside of neurons and
glia cells (Lee et al., 2001; Jeganathan et al., 2008). Interestingly, evidence suggests that accumulation of tau correlates
with brain atrophy and clinical symptoms in Alzheimer’s
disease patients and other tauopathies (Nelson et al., 2012;
Brier et al., 2016; Johnson et al., 2016). Several studies have
illustrated that tau pathology appears to propagate from cell
to cell in a prion-like fashion by an as-yet-unknown mechanism. Some data suggest that pathological tau escapes extracellularly, thereby entering neighboring cells transsynaptically
(de Calignon et al., 2012; Lasagna-Reeves et al., 2012; Ahmed
et al., 2014; Yamada et al., 2014; Clavaguera et al., 2015). If
extracellular pathological tau mediates cell to cell spreading,
tau binding agents that can access extracellular tau, such as
anti-tau antibodies, might be a valuable tool to prevent uptake
of extracellular tau into neurons or other cells to decrease
spread of tau pathology. Recently, it has been shown that pas-
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sive immunization with different anti-tau antibodies can have
beneficial effects on tau pathology (Boutajangout et al., 2011;
Chai et al., 2011; d’Abramo et al., 2013; Castillo-Carranza et
al., 2015; Sankaranarayanan et al., 2015).
In line with this, we have previously developed an antibody that blocks cellular tau seeding activity very efficiently
(Yanamandra et al., 2013; Holmes et al., 2014). Passive immunization with this anti-tau antibody, HJ8.5, decreased overall
tau accumulation and slowed progression of the disease in a
human P301S tau–expressing transgenic (P301S-tg) mouse
model (Yanamandra et al., 2013, 2015). Although these results demonstrated the neuroprotective effects of a specific
anti-tau immunotherapy, the mechanisms by which this and
other anti-tau antibodies prevent pathological tau accumulation remain unknown. Further, treatment of brain diseases
with antibodies remains a challenge in humans because only
a small percentage of antibodies in the plasma are able to cross
the blood–brain barrier (Yanamandra et al., 2015). Therefore,
we set off to focus on understanding the mechanism by which
that anti-tau antibody HJ8.5 acts, to determine whether we
could improve brain delivery and, importantly, investigate the
requirement of the Fc domain of the HJ8.5 antibody in decreasing tau pathology. The latter requirement was assessed
by using single-chain variable fragments (scFvs) in a gene
therapy approach targeting the central nervous system (CNS).
ScFvs, which consist of the variable region of the heavy and
the light chain connected by different peptide linkers, have

Abbreviations used: AAV, adeno-associated virus; CNS, central nervous system; CSF,
cerebrospinal fluid; FA, formic acid; FRET, fluorescence resonance energy transfer;
HA, hemagglutinin; htau, human tau; ICV, intracerebroventricular; ISF, interstitial
fluid; scFv, single-chain variable fragment; SPR, Surface plasmon resonance.
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been shown to retain their antigen-binding specificity and,
because of their small size, yield good tissue penetration and
can be easily packed into an adeno-associated virus (AAV) for
therapeutic delivery in the CNS (Ahmad et al., 2012).
To date, very little is known about the role of FcγRs on
microglia in the neuroprotective effects of anti-tau immunotherapy. These protective effects could result either from
sequestration of extracellular tau blocking cellular entrance
and/or signaling or from IgG binding to FcγRs expressed
on microglia that facilitate extracellular tau clearance. However, the latter may also result in a proinflammatory response
and the development of adverse effects that potentially exacerbate the degenerative process (Lee et al., 2016) or even
an increase in tau seeding and spreading (Asai et al., 2015).
A major safety concern from early immunotherapies targeting Aβ was the development of vascular side effects that
led to the discontinuation of an early clinical trial and have
continued to be seen with some anti-Aβ antibodies (Senior,
2002; Nicoll et al., 2003; Orgogozo et al., 2003; Sevigny et
al., 2016). Subsequently, histopathological studies implicated
activation of FcγRs on microglia after immunotherapy in
the development of these adverse effects (Adolfsson et al.,
2012; Freeman et al., 2012).
Here, we show that anti-tau scFvs can be efficiently
delivered to the brain by AAV2/8-mediated gene transfer,
where they are predominantly expressed by neurons and astrocytes. The scFvs retained their antigen-binding specificity,
and their expression led to a marked decrease of pathological
tau accumulation in the hippocampus of P301S-tg mice. Depending on the linker used, we were able to detect secreted
scFvs in the picomolar to low-nanomolar range in the cerebrospinal fluid (CSF). Interestingly, despite their effects on tau
pathology, they did not affect absolute human tau (htau) levels
in the CSF. Our studies provide a strategy for generating immunotherapeutics with an improved efficacy that potentially
limits a proinflammatory response that may be detrimental.
RESULTS AND DISCUSSION
Length of the linker defines binding
properties of anti–htau scFvs
Work over the past decades has shown that scFvs with the
orientation VL-linker-VH show a greater binding capacity
than VH-linker-VL constructs. Furthermore, the length of
the linker influences not only efficient folding and solubility
but also affinity of the scFvs (Desplancq et al., 1994; Sheikholvaezin et al., 2006). Based on these studies, we designed
three anti-tau scFvs that differ only in the length of the glycine-based peptide linker that connects the variable region
of the light (VL) and the heavy chain (VH). A secretory signal
peptide was added at the N terminus and a hemagglutinin
(HA) tag at the C terminus to facilitate detection (Fig. 1 A).
First, we confirmed expression and secretion of all three scFvs
(SC1, SC2, and SC3 scFv) in vitro. HEK293T cells were
transfected with the scFv constructs, and their presence was
confirmed in cell lysates as well as culture supernatants by im1228

munoblot analysis (Fig. 1 B, bottom). To determine whether
they retained their ability to bind to tau, the culture supernatant was mixed with recombinant htau, and coimmunoprecipitation was performed. Immunoblot analysis confirmed
binding of the scFvs to htau (Fig. 1 B, top). To determine the
specificity of anti-tau scFvs, brain lysates from P301S-tg mice
and nontransgenic controls were subjected to immunoblotting analysis using purified scFvs. Notably, immunoblotting
for htau revealed that all three scFvs effectively immunoreacted with htau and not mouse tau (Fig. 1 C). Additionally,
surface plasmon resonance (SPR) measurements with immobilized htau revealed varying binding constants (KD) for all
three scFvs, with SC1 scFv displaying the lowest and SC2
scFv the highest KD (Fig. 1 D). Collectively, these analyses
validated that our anti-tau scFvs retain biological activity that
is specific for htau, with different binding affinities.
Functional anti-tau scFvs can be expressed in the brain
in vivo by AAV-mediated gene transfer
Based on our SPR data (Fig. 1 D), we decided to test the scFv
with the slowest dissociation rate (SC1 scFv) and that with
the fastest association rate (SC3 scFv) in vivo. Therefore, the
scFvs were packaged into AAV2/8 and delivered at postnatal
day 0 (P0) by bilateral intracerebroventricular (ICV) injections. Immunohistological staining with an anti-HA antibody
revealed widespread expression of the scFvs throughout the
brain at 3 mo after injection (Fig. 2 A). In line with a previous
study (Chakrabarty et al., 2013), costaining with a neuronal
(NeuN; Fig. 2 B), astrocytic (GFAP; Fig. 2 C), or microglial
(Iba1; Fig. 2 D) marker revealed expression mostly in neurons
and astrocytes, but rarely microglia. Furthermore, coimmunoprecipitation from brain lysates of AAV-injected P301S-tg
mice showed that the scFvs retain their biological activity to
bind htau (Fig. 2 E). In addition to expression in the brain,
we detected scFvs in liver, heart, lung, and muscle samples
of these mice (Fig. 2 F), showing that the AAV expression is
not restricted to the brain despite ICV injections. However,
we did not observe any gross changes in tissue morphology
in 16-wk-old mice as assessed by hematoxylin and eosin
staining (not depicted). Furthermore, immunoblot analysis
failed to detect any scFvs in plasma samples (Fig. 2, G and H),
most likely because of the short half-life of scFvs in plasma.
Thus, AAVs can be used to express scFvs in the brain while
retaining scFv function.
SC1 and SC3 scFvs affect soluble tau levels
and decrease p-tau staining in specific hippocampal
regions in aged P301S-tg mice
After validating expression of the scFvs and confirming their
binding capabilities to htau, we aged AAV2/8 scFv-injected
P301S-tg mice to 9 mo to investigate effects on tau pathology.
P301S-tg mice begin to develop tau pathology at 5–6 mo,
and it is robust by 9 mo of age. As a control, we injected mice
with an AAV2/8 expressing an scFv with no binding affinity
for any mouse protein. Immunoblot analysis of brain lysates
Anti-tau scFvs decrease tau accumulation in vivo | Ising et al.

Figure 1. Length of the linker defines binding properties of anti–htau-scFvs. (A) Graphical representation of the three scFvs used. VL, variable region
of the light chain; VH, variable region of the heavy chain; SP, secretory signal peptide; HA, HA-epitope tag. (B) Coimmunoprecipitation (IP) with an anti-HA
antibody after mixing cell culture supernatants of scFv-transfected HEK 293T cells with recombinant (rec.) human P301S tau shows coprecipitation of
human P301S tau with all scFv variants when analyzed by immunoblot (n = 3). (C) Immunoblot analysis of brain lysates from WT and P301S-tg mice as well
as recombinant human P301S and mouse WT tau with scFvs used as a primary antibody shows specificity of the scFvs to htau with no detection of mtau (n
= 3). (D) SPR measurements were performed after binding of htau to the surface and floating purified scFvs in the flow cell. Association rate (Ka), dissociation
rate (Kd), and binding constant (KD) are different for all scFv variants. RU, relative units. Values for full-length HJ8.5 in the table in D are from the original
publication (Yanamandra et al., 2013). Results are representative for three independent experiments for B and C and one experiment for D.
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Figure 2. Functional anti-tau scFvs can be expressed in the brain in vivo by AAV-mediated gene transfer. (A) Immunohistochemical staining
(anti-HA) of brain sections from a mouse that received an ICV injection of AAV2/8 SC3 scFv at P0 and was analyzed 3 mo later. The scFvs showed good
expression throughout the brain (n = 6). Bar, 1 mm. (B–D) Immunofluorescence staining of brain sections from AAV2/8 scFv–injected mice with an HA anti-
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confirmed expression of the scFvs in all aged mice used in
this study (Fig. S1, A–C). At 9 mo of age, control scFv–treated
mice displayed a substantial amount of abnormally phosphorylated htau (p-tau) in the hippocampus (stained by AT8, detecting paired helical filament tau phosphorylated at Ser202
and Thr205).Treatment with either SC1 or SC3 scFv revealed
a nonsignificant trend toward lowering the levels of p-tau in
assessing the entire hippocampus (Fig. 3, A and B). However,
when assessing specific hippocampal subregions, there was
significantly lower p-tau staining in SC1 scFv–treated mice in
the CA1 cell body region (Fig. 3 C) as well as the CA1 stratum radiatum (Fig. 3 D) compared with control scFv–treated
mice. Because of high variability, the effect did not quite reach
statistical significance for SC3 scFv–treated mice in either region (Fig. 3, C and D). To determine soluble and insoluble
htau levels, we performed sequential biochemical extractions.
Hippocampus samples were first extracted in a high salt
buffer (RAB buffer), before the remaining pellet was resuspended in a detergent-containing buffer (RIPA). The final
pellet containing highly insoluble tau species was solubilized
in a 70% formic acid (FA) solution. ELISA measurements revealed significantly higher levels of RAB-soluble htau in SC1
scFv–treated mice and the same nonsignificant trend for SC3
scFv–treated mice (Fig. 3 E). This finding was accompanied
by a strong and significant decrease in htau in RIPA fractions
after both treatments (Fig. 3 F). Expression of either scFv did
not affect FA-soluble tau levels (Fig. 3 G). Next, we looked
at levels of scFvs in RAB fractions and detected similar levels
of SC1 and SC3 scFvs (Fig. S1 D). To validate binding of
the scFvs to htau, we performed tau-scFv complex–specific
ELISAs. These analyses demonstrated that both SC1 and SC3
scFvs are detectable in a complex with htau in hippocampal RAB fractions (Fig. S1 E). Interestingly, further analysis
revealed a negative correlation for RAB-soluble htau levels
with AT8 staining in the hippocampus (Fig. S2 A), whereas
there was no correlation for RIPA-soluble htau (Fig. S2 B)
and there was a positive correlation for insoluble htau levels
(Fig. S2 C). Collectively, SC1 and SC3 scFvs decrease tau pathology as seen by p-tau staining, whereas total htau appears
to be shifted from RIPA-soluble to RAB-soluble fractions.
SC1 and SC3 scFvs are detectable in CSF but do not
significantly alter tau levels
Because we hypothesized a role for extracellular tau in the
progression of tau pathology, we set out to determine a poten-

tial effect of the scFvs on the levels of extracellular tau. htau
levels in CSF decrease over time in P301S-tg mice.Therefore,
we wanted to look at time-dependent differences. First, we
collected CSF from young (3–4.5 mo old) P301S-tg mice
and analyzed levels of secreted scFvs by an indirect ELISA.
Here, SC1 and SC3 scFvs were detectable in CSF samples of
all mice, with SC3 scFv displaying a ∼40× higher level than
SC1 scFv (∼263 pM for SC1 scFv vs. ∼10 nM for SC3 scFv;
Fig. 4 A). Because similar levels of SC1 and SC3 scFvs are
present in brain tissue (Fig. S1, D and E), this suggests a longer
extracellular half-life of SC3 scFv. Analysis of htau levels in the
CSF by an ELISA using a Simoa HD analyzer showed no significant differences between groups despite a trend to lower
htau levels in SC3 scFv–treated mice (Fig. 4 B). In addition,
we collected interstitial fluid (ISF) from the same mice by in
vivo brain microdialysis and assessed htau levels by ELISA. Interestingly, we observed the same trend toward lowering htau
in the ISF of SC3 scFv–treated mice (Fig. S3 A). htau levels
in ISF and CSF correlated well when SC1 scFv– and SC3
scFv–treated mice were analyzed (Fig. S3 B) but showed no
correlation in control scFv–treated mice (Fig. S3 C), pointing
to a potentially different clearance mechanism for htau in the
presence of either SC1 or SC3 scFv. To confirm binding of
the scFvs to extracellular tau, we performed coimmunoprecipitation experiments from ISF samples. Immunoblot analysis confirmed binding of the scFvs to tau (Fig. S3 D).
In CSF samples of aged (9 mo old) P301S-tg mice, we
found a difference in the levels of SC1 and SC3 scFvs (Fig. 4 C)
similar to that seen in young mice (∼116 pM for SC1 scFv
vs. ∼4 nM for SC3 scFv; Fig. 4 C). Analysis of htau levels in
the CSF showed no significant differences between groups
despite a trend to lower htau levels in both SC1 scFv– and SC3
scFv–treated mice (Fig. 4 D). Of note is that the concentration
of htau in CSF of the young P301S-tg mice was ∼20 pM or
10× lower than the concentration of SC1. In addition to possible effects on clearance, binding of scFvs to extracellular tau
could potentially influence pathology by preventing tau uptake
into neurons. To test this idea, we treated neuroblastoma cells
(N2a cells) and primary cortical neuronal cultures with fluorescently labeled tau in the presence and absence of scFvs and
analyzed uptake by flow cytometry. Interestingly, both scFvs
were able to decrease tau uptake into both cell types (Fig. S3,
E and F). Furthermore, we determined the effect of the scFvs
on seeding activity by using biosensor cells, which express a
repeat-domain tau-YFP and -CFP construct. Seeding can be

body revealed expression of scFvs by neurons (B; NeuN) and astrocytes (C; GFAP), but rarely microglia (D; Iba1). n = 5 for each costaining; images represent
maximum-intensity projections of z-stacks. Bars: (overview) 50 µm; (magnification) 10 µm. (E) Immunoblot analysis of cortex lysates (bottom) from mice
injected with either AAV2/8 SC1 scFv or AAV2/8 SC3 scFv showed expression of the scFvs in all analyzed mice. Immunoprecipitation (IP) experiments (top)
with an HA antibody showed coprecipitation of htau from mice that expressed the human P301S tau transgene, but not WT mice. Immunoblot is representative of two independent experiments that were performed with at least three P301S-tg mice per group. (F) Immunoblot analysis of different organs
showed expression of scFvs in liver, heart, lung, and muscle lysates of mice 2.5 mo after ICV injection of AAV2/8 scFvs. Immunoblot is representative of eight
independent experiments (n = 4 for SC1 scFv and SC3 scFv, respectively). (G and H) SC1 and SC3 scFvs were undetectable by immunoblot analysis of plasma
samples from mice 2.5 mo after ICV injection of AAV2/8 scFvs (n = 6 for SC1 scFv and n = 7 for SC3 scFv).
JEM Vol. 214, No. 5
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Figure 3. SC1 and SC3 scFvs affect soluble tau levels and decrease p-tau staining in specific hippocampal regions in aged P301S-tg mice.
(A) Hippocampus of AAV2/8 scFv-injected mice after immunohistochemical staining with anti-AT8, a phospho-tau antibody. Images are representative of
animals stained in one histochemical experiment (n = 17 for control scFv, n = 13 for SC1 scFv, and n = 16 for SC3 scFv). Arrow, CA1 cell body layer; arrowhead, stratum radiatum. Bars, 500 µm. (B) Quantification of percentage of area covered by AT8 showed a nonsignificant trend to lower phospho-tau in the
full hippocampus (P = 0.25 by one-way ANOVA). (C and D) Quantification of percentage of area covered by AT8 showed significantly lower phospho-tau
levels in CA1 cell bodies (C; *, P = 0.02 by one-way ANOVA) and the stratum radiatum (D; *, P = 0.04 by one-way ANOVA) in SC1 scFv–treated mice and
nonsignificant trends for SC3 scFv–treated mice. (E–G) htau-specific ELISAs revealed significantly increased RAB-soluble tau in the hippocampus of SC1
scFv–treated mice (E; **, P = 0.006 by one-way ANOVA), decreased levels of RIPA-soluble tau in SC1 scFv– and SC3 scFv–treated mice (F; ***, P = 0.0002 by
one-way ANOVA), and no difference in FA-soluble (G; P = 0.67 by one-way ANOVA) tau levels (n = 17 for control scFv, n = 14 for SC1 scFv, and n = 16 for
SC3 scFv). (B–G) All graphs are means ± SEM and were analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison post hoc test comparing
every column to control scFv: *, P < 0.05; **, P < 0.01; ***, P < 0.001.

induced by applying extracellular tau, which can then be quantified by measuring the fluorescence resonance energy transfer
(FRET) signal by flow cytometry (Holmes et al., 2014).To test
whether the scFvs can inhibit seeding, we immunodepleted
tau from brain lysates of P301S-tg mice with the scFvs and
applied those samples to the biosensor cells. Quantification of
the resulting FRET signal revealed a significant decrease in
seeding activity in the immunodepleted lysates compared with
1232

control-treated samples (Fig. S3 G). Thus, SC1 and SC3 scFvs
are efficiently secreted but, despite substantial levels in the CSF,
do not significantly affect overall total htau levels in the CSF
or ISF but could potentially inhibit tau uptake and seeding.
Concluding remarks
In conclusion, we demonstrate that the length of the linker
influences binding properties of scFvs to htau. ICV injection
Anti-tau scFvs decrease tau accumulation in vivo | Ising et al.

Figure 4. SC1 and SC3 scFvs are detectable
in CSF but do not significantly alter tau levels. (A) Analysis of CSF from young (3–4.5 mo old)
P301S-tg mice by ELISA revealed levels of SC1
scFvs in the low-nanomolar range (7.7 ± 2.5 ng/
ml; ∼263 pM) and high levels (313 ± 39.2 ng/ml;
∼10 nM) of SC3 scFvs (n = 7 for SC1 scFv and n
= 11 for SC3 scFv). (B) Analysis of htau levels in
CSF samples of young P301S-tg mice by using a
homebrew Simoa assay showed no significant difference between groups (n = 8 for control scFv, n =
6 for SC1 scFv, and n = 10 for SC3 scFv; P = 0.20 by
one-way ANOVA). (C) ELISA measurements of scFv
levels in CSF samples of 9-mo-old P301S-tg mice
showed similar differences in scFv levels between
SC1 scFv– and SC3 scFv–treated mice as seen in
young mice (3.4 ± 0.5 ng/ml [∼116 pM] for SC1
scFv and 118.7 ± 17.4 ng/ml [∼4 nM] for SC3 scFv;
n = 12 for SC1 scFv and n = 16 for SC3 scFv). (D)
Analysis of htau levels in CSF samples of 9-mo-old
P301S-tg mice by using a homebrew Simoa assay
showed no significant difference between groups
(n = 17 for control scFv, n = 12 for SC1 scFv, and
n = 15 for SC3 scFv; P = 0.51 by one-way ANOVA).
(A–D) All graphs represent means ± SEM.

of AAV2/8 scFvs at P0 led to widespread expression of the
constructs throughout the brain, where they retained their
antigen-binding capability and bound tau in the brain in
vivo. Furthermore, expression of the scFvs strongly reduced
p-tau and detergent-soluble tau accumulation in P301S-tg
mouse hippocampus. Finally, we confirmed secretion of scFvs
into the extracellular space, but intriguingly did not detect
significantly altered total extracellular tau levels despite evidence of scFvs binding to extracellular tau and effects of
scFvs on tau pathology.
Collectively, these results suggest that microglialmediated tau clearance is likely not mandatory in the mechanism by which anti-tau antibodies are protective against tau
accumulation. To our knowledge, this is the first study to report effects of scFv’s targeting of tau to reduce tau pathology.
One recent study found that p-tau staining was reduced after
peripheral administration with a full-length anti–phospho-tau
antibody with an effectorless Fc region mutation (Lee et al.,
2016). The mechanism of the effect was not clear, as assessment of binding to tau in vivo or biochemical tau levels was
not performed. Sankaranarayanan et al. (2015) recently reported reduced CSF tau levels after peripheral treatment with
a full-length anti–phospho-tau antibody.These results are difficult to compare to our study because of major differences
in study design. Although their group used a full-length anJEM Vol. 214, No. 5

tibody to treat rTg4510 transgenic mice, which show higher
CSF tau levels in general, we used scFvs to treat P301S-tg
mice. Although we did not observe an effect on total CSF
tau after expression of the scFvs, we did observe binding of
the scFvs to tau in the brain and ISF. This suggests that the
clearance of a tau-scFv complex is likely to take on the clearance pathway of the secreted scFvs. Such binding may not
alter total tau levels if the half-life of scFv-tau complexes is
similar to that of unbound tau. However, such binding could
alter clearance pathways of the scFv-tau complex. Clearance
of scFv-tau complexes from the brain is likely to involve the
brain’s glymphatic system and lymphatics into CSF, neck
lymph nodes, and blood as opposed to local clearance by microglia. We did observe a positive correlation between CSF
htau and ISF tau, which is seen only in scFv-treated but not
control mice.This suggests that anti-tau scFv–mediated clearance mechanisms act in concert with blocking tau uptake,
seeding, and possibly signaling, the detailed mechanism of
which can be addressed in future studies.
With regard to the development of therapeutics for
tauopathies, this study could have several important implications. First, scFvs have the advantage of more efficient brain
diffusion over full-length antibodies in passive immunotherapy after CNS gene transfer or direct CNS infusion (Huang
et al., 2013). Second, scFvs can be cost-efficiently produced in
1233

bacteria (Ahmad et al., 2012) whereas full-length antibodies
usually have to be expressed and purified from mammalian
cells. Third, lack of the Fc domain in scFvs reduces potential immunogenicity (Huang et al., 2013; Lee et al., 2016),
thereby reducing the risk of inflammation-related side effects.
Fourth, AAV-mediated gene transfer for therapeutic delivery
could potentially be a feasible method for therapeutic delivery of scFvs. Interestingly, AAV-mediated gene transfer to
the CNS is already being used successfully in clinical trials to
treat several other diseases (Kantor et al., 2014). Combining
this approach with the less immunogenic scFvs—which are
already tested as therapeutic agents in clinical trials for other
diseases (Ahmad et al., 2012)—might be a valuable tool in
future therapeutic applications for brain disorders in general
and tauopathies in particular.
MATERIALS AND METHODS
Animal procedures and sample collection
P301S tau transgenic mice (line PS19, purchased from The
Jackson Laboratory) express the P301S human T34 isoform
(1N4R) under control of the prion protein promoter. These
mice are on a B6C3 background and were generated and
characterized previously (Yoshiyama et al., 2007). Animal
procedures were performed according to protocols approved
by the Animal Studies Committee at Washington University
School of Medicine. For AAV expression, pups received a bilateral ICV injection on P0 of 2 µl AAV (2.5 × 1013 vg/
ml). Because of the reported high variability in tau pathology
between aged male and female P301S-tg mice (Zhang et al.,
2012; Yanamandra et al., 2013), we used only males for the
study in which mice were aged to 9 mo, but mixed genders
whenever young (3–4.5 mo old) mice were used. At time
of death, mice were anesthetized and CSF was collected as
described previously (DeMattos et al., 2002). Blood samples
were collected in EDTA-treated tubes before cardiac perfusion with PBS/heparin. Blood samples were spun down (10
min, 2,000 g, 4°C), and blood plasma was collected. Brains
were taken out, one hemisphere dissected and the other
hemisphere immersion fixed in 4% paraformaldehyde. After
24 h, paraformaldehyde was exchanged with 30% sucrose and
the brain was incubated for 48 h in this solution before it was
frozen with 2-methylbutane on dry ice. Frozen brains were
kept at −80°C before they were sectioned on a microtome
(50-µm thickness). Floating sections were kept in 24-well
plates with 30% ethylene glycol, 15% sucrose, and 0.2 M sodium phosphate at −20°C.
Antibodies
Biotinylated and unbiotinylated anti-HJ8.5 (htau-specific
antibody; Yanamandra et al., 2013), anti HJ8.7 (detects htau
and mouse tau [mtau]; Yanamandra et al., 2013), and anti-Tau5 (htau specific; Yanamandra et al., 2013) were used.
Anti-NeuN and anti-GFAP were purchased from EMD Millipore, and anti-Iba1 was from Wako Pure Chemical Industries. Biotinylated and unbiotinylated anti–htau (clone HT7),
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biotinylated phospho-htau (clone AT8), and fluorescently labeled secondary antibodies were obtained from Invitrogen.
Biotinylated peroxidase-coupled secondary antibodies were
from Jackson ImmunoResearch Laboratories, Inc., and fluorescently labeled streptavidin was from Molecular Probes.
Biotinylated anti-HA was purchased from Vector Laboratories and Bethyl Laboratories, Inc., and peroxidase-coupled
anti-HA was from Roche. Anti-HA agarose beads and anti-actin were obtained from Sigma-Aldrich.
Biochemical extraction of different tau species
Frozen brain pieces were weighed, and 30 µl RAB buffer per mg of tissue added (RAB buffer = 0.75 M NaCl,
0.1 M MES, 1 mM EGTA, 0.5 mM MgSO4, 2 mM DTT,
and 1 mM Na3VO4, pH 6.8). Samples were sonicated on
ice for 1 min (FB120; Thermo Fisher Scientific; 30% amplitude, 1-s intervals) before spinning them at 50,000 g (20
min, 4°C). The supernatant was collected (RAB fraction,
contains salt-soluble tau) before adding RIPA buffer (0.15 M
NaCl, 50 mM Tris, 25 mM EDTA, 1% Triton X-100, 0.5%
sodium deoxycholate, and 0.5% SDS, pH 8.0) at 30 µl/mg
tissue (RIPA buffer = 0.15 M NaCl, 50 mM Tris, 25 mM
EDTA, 1% Triton X-100, 0.5% sodium deoxycholate, and
0.5% SDS, pH 8.0). After another round of sonication, samples were centrifuged at 50,000 g (20 min, 4°C). Supernatant
was collected (RIPA fraction, contains detergent-soluble tau),
and 10 µl of 70% FA solution per mg of tissue was added.
Sonication and centrifugation and collection of supernatant
(FA fraction, contains insoluble tau) were repeated. RAB and
RIPA buffers were supplemented with 1× PhosSTOP and
1× cOmplete (Roche). All samples were stored at −80°C;
before performing ELISA assays, FA fractions were neutralized with 1 M Tris, pH 11.
Coimmunoprecipitation
HEK293T cells were transiently transfected with Lipofectamine 2000. 48 h after transfection, supernatant was collected.
After centrifugation at 1,500 g (5 min, room temperature), a
small aliquot of each supernatant fluid was preserved and diluted with immunoblot sample buffer for immunoblot analysis (i.e., supernatant). The remaining supernatant was mixed
with 10 µl anti-HA agarose beads (Sigma-Aldrich) and 1 µg
recombinant human P301S tau. For coimmunoprecipitation
from brain lysates, cortex pieces were homogenized in a modified RIPA buffer (50 mmol/L Tris-HCl, pH 7.4, 1% NP-40,
0.25% sodium deoxycholate, 150 mmol/L NaCl, 1 mmol/L
EDTA, and protease inhibitors) and incubated on ice for 15
min. After centrifugation at 20,000 g (15 min, 4°C), a small
aliquot of each supernatant fluid was preserved and diluted
with immunoblot sample buffer for immunoblot analysis (i.e.,
lysate). Protein concentration was determined by BCA assay,
and 100 µg protein lysate was mixed with 10 µl anti-HA agarose beads in modified RIPA buffer.
After incubation for 1 h at room temperature, the agarose beads were washed extensively with PBS, and bound
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proteins were eluted by boiling the beads in immunoblot
sample buffer (i.e., HA-IP).
For coimmunoprecipitation from ISF, samples were collected by in vivo brain microdialysis from SC3 scFv–injected
mice. SC3 scFv concentrations were determined by ELISA,
and a sample volume containing ∼800 pg SC3 scFv was used
for the IPs. As a control, ISF sample buffer was mixed with
purified SC3 scFvs at the same concentration. 5 µg anti-tau
antibody (HJ8.7) was added to each tube, and the samples
were incubated for 2 h on a rotator at 4°C. After addition of
20 µl protein G Sepharose beads (GE Healthcare), the tubes
were rotated at 4°C for another 2 h. Beads were washed once
with cold PBS before bound proteins were eluted by boiling
the beads in immunoblot sample buffer (i.e., tau-IP). Proteins were resolved by NuPAGE Novex 4–12% Bis-Tris gels
(Thermo Fisher Scientific), blotted onto nitrocellulose membranes, and visualized with enhanced chemiluminescence
after incubation of the blots with the respective antibodies.

Immunofluorescence
Sections were mounted on gelatin-coated slides and air-dried
for 30 min. After extensive washing with PBS, sections were
blocked with 5% normal goat serum in PBS with 0.1% Triton X-100. After washing, sections were incubated with primary antibodies diluted in PBS overnight at 4°C followed
by three more wash steps. Fluorescently labeled secondary
antibodies or streptavidin were diluted in PBS and applied to
the sections. After washing, sections were coverslipped with
Prolong Gold with DAPI (Invitrogen). Images were taken as
a z-stack (one image every 1.5 µm) with a Nikon A1Rsi with
a 40× oil immersion objective operated by NIS-Elements
AR software version 4.30.02 (Nikon). Images were further
processed with the use of ImageJ/Fiji software version 2.0.0
(National Institutes of Health) and Photoshop CS6 version
13.0.1 (Adobe Systems).

ELISA
To measure unbound scFvs, an indirect ELISA procedure was
applied. Half-well 96-well plates were coated overnight at 4°C
with 50 ng/ml recombinant human WT tau. After extensive
washes with PBS, the wells were blocked with 4% BSA in
PBS before diluted samples (sample buffer: 0.25% BSA and
300 mM Tris, pH 8.0, in PBS with protease inhibitors) were
incubated overnight at 4°C. After washing, the wells were
incubated with a biotinylated HA antibody (Bethyl Laboratories, Inc.) for 1.5 h. For htau-specific measurements or to
detect htau–scFv complexes in brain homogenates, a sandwich
ELISA was used. Plates were coated with Tau5 antibody and
blocked with 4% BSA in PBS. Samples were diluted in sample
buffer and, as a detector antibody, either biotinylated anti–
htau (clone HT7) or biotinylated anti-HA was used. All ELI
SAs were developed with super-slow TMB substrate solution
(Sigma-Aldrich) before reading on a plate reader at 650 nm.

Immunohistochemistry
Sections were stained in a free-floating format in a 12-well
plate.After extensive washing with TBS, sections were blocked
with 0.3% hydrogen peroxide for 10 min. After washing, sections were blocked for 30 min in 3% milk in TBS and 0.25%
Triton X-100 (TBS-X). The respective biotinylated primary
antibody was diluted in 3% milk in TBS-X, and the sections
were incubated overnight at 4°C. After washing, sections were
incubated with ABC solution (VectaStain) according to the
manufacturer’s instructions, followed by another three wash
cycles. Sections were developed in DAB solution (SigmaAldrich), washed, and mounted on slides. After drying overnight, sections were dehydrated in increasing ethanol concentrations followed by xylene. Slides were coverslipped with
Cytoseal 60 (Thermo Fisher Scientific) and scanned on a
NanoZoomer 2.0-HT system (Hamamatsu Photonics). Images were further processed and quantified with the use of ImageJ/Fiji software version 2.0.0. All areas were quantified in at
least four sections (300 µm apart from each other) per mouse.

Generation and purification of scFvs
HJ8.5 monoclonal antibody was raised by immunizing
tau-knockout mice with htau as described previously (Yanamandra et al., 2013). This antibody recognizes amino acids
25–30 of the full-length human 1N4R sequence (Yanamandra et al., 2013). After sequencing, the variable regions
were cloned and combined in one plasmid connected by a
(GGGS)1-linker. A secretory signal peptide was added at the
N terminus and an HA-tag at the C terminus. The different
linker sequences were introduced by site-directed mutagenesis. For purification, Expi293F cells (Gibco) were grown
in Expi293 Expression Medium (Gibco) to a density of 106
cells/ml before they were transiently transfected with Lipofectamine 2000 (Invitrogen). The scFvs were affinity-purified
from supernatant 4 d later by using a HiTrap Protein L column
(GE Healthcare) according to the manufacturers’ instructions.
After elution, the scFvs were dialyzed in PBS and concentrated with an Amicon Ultra 10K device (EMD Millipore).

In vivo microdialysis
In vivo brain microdialysis was performed as described previously (Yamada et al., 2014). In brief, bore holes were made
above the left hippocampus (AP −3.1 mm, ML −2.5 mm,
DV −1.2 mm). A guide cannula (Eicom Microdialysis) was
stereotactically inserted in the left hippocampus (12° angle)
and cemented. After a recovery period and habituation to
the Raturn sampling caging system (BASi), a 2-mm 1,000kD MWCO cutoff AtmosLM microdialysis probe (Eicom)
connected to a peristaltic push-pull pump (SciPro) was inserted through the guide cannula. As a perfusion buffer, 25%
human albumin solution (Gemini Bio) was diluted to 4%
with artificial CSF (1.3 mM CaCl2, 1.2 mM MgSO4, 3 mM
KCl, 0.4 mM KH2PO4, 25 mM NaHCO3, and 122 mM
NaCl, pH 7.35). ISF samples were collected at a flow rate
of either 1 or 0.5 µl/min in a refrigerated microsampler
(Univentor). Analysis by ELISA was performed at the completion of each experiment.
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Recombinant AAV production
All scFvs were cloned into the AAV vector under control of
the chicken β-actin promoter. The rAAV2/8-scFvs used in
these studies were prepared at the Hope Center Viral Vectors
Core at Washington University School of Medicine.
Recombinant htau
Recombinant human P301S (1N4R) and WT tau (2N4R)
were cloned into pRK172 and purified as described previously (Goedert and Jakes, 1990). Aliquots were frozen at
−80°C for one-time use. For tau uptake assays, 200 µl of a
8-µM recombinant human P301S tau solution was incubated with 0.025 mg Alexa Fluor 647 NHS ester (Molecular Probes) for 1 h at room temperature before the mixture
was moved to 4°C overnight. Free dye was quenched with
100 mM glycine before the sample was dialyzed in PBS.
Seeding assay
Seeding with the biosensor cells was performed as described
previously (Holmes et al., 2014). In brief, htau concentration
in RAB lysates from P301S-tg mice was measured by ELI
SA. Lysate containing 7 nM htau was immunodepleted by
incubation with 700 nM scFvs (100×) and anti-HA beads for
1 h at 4°C. After a brief centrifugation, the supernatant was
diluted with PBS and mixed with Lipofectamine 2000 before
adding it to the biosensor cells in a 96-well plate. Cells were
incubated for 24 h before the cells were trypsinized, fixed, and
resuspended in flow buffer (1× HBSS with 1% FBS and 1 mM
EDTA).The number of cells with a FRET signal was analyzed
on a MACSQuant VYB flow cytometer. Data analysis was
performed with FlowJo Version 10 and analyzed as percentage
of cells with a FRET signal within the single cell population.
Simoa assays
To measure htau in CSF samples, a Simoa homebrew assay was
developed. Paramagnetic carboxylated beads (Quanterix) were
activated with 0.3 mg/ml 1-ethyl-3-(3-dimethylaminopropyl)
carbodiimide hydrochloride (EDC;Thermo Fisher Scientific)
and coated with 0.3 mg/ml anti-HJ8.7 (binds to htau and
mtau) according to the manufacturer’s instructions. For detection, anti–htau (clone HT7) was biotinylated at a 40× molar
ratio and used at a final concentration of 0.6 µg/ml with a SBG
enzyme (Quanterix) concentration of 350 pM.All samples and
standards were diluted in tau calibrator diluent (Quanterix) and
run on a Simoa HD-1 analyzer (Quanterix) as a two-step assay.
Statistical analysis
All graphs represent means ± SEM. Statistical analysis was performed with GraphPad Prism 5.01 using one-way ANOVA
with Dunnett’s post hoc test comparing every group to
the control-treated group.
SPR
SPR experiments were performed as described previously
(Yanamandra et al., 2013). In brief, a Biacore sensor chip
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CM-5 was activated in a BIAcore 2000 SPR instrument (GE
Healthcare-BIAcore) by using a 1:1 ratio of EDC and N-hydroxysuccinimide (NHS). Recombinant human WT tau in
10 mM sodium acetate, pH 3.5, was immobilized on the sensor chip surface with a flow rate of 5 µl/min. The remaining
unbound area was blocked by 1 M ethanolamine, pH 8.5. For
reference, one flow cell was activated, followed by blocking
with 1 M ethanolamine. All scFvs were injected at different
concentrations (6.25, 12.5, 25, 50, 100, 200, and 400 nM) in
filtered, degassed 0.01 M Hepes buffer, 0.15 M NaCl, 0.005%
surfactant P20, pH 7.4, at a flow rate of 10 µl/min. All samples were run in duplicate. After each run with a single antibody concentration, the surface of the chip was regenerated
by using 10 mM glycine, pH 1.7. Data analysis was performed
by using BIAevaluation software (GE Healthcare-BIAcore).
Association (Ka) and dissociation (Kd) were calculated using
Fit kinetics simultaneous Ka/Kd (global fitting) with a 1:1
(Langmuir) interaction model.
Tau uptake assay
Undifferentiated neuroblastoma cells (N2a) were split at
25,000 cells/well in a poly-l-lysine–coated 96-well plate 24 h
before the start of the experiment. For uptake assays with primary cortical neurons, neurons were prepared as described
previously (Beaudoin et al., 2012) and plated at 50,000 cells/
well in a poly-l-lysine–coated 96-well plate. Uptake experiments were performed on 7–9 d in vitro. 20-nM Alexa
Fluor 647–labeled recombinant human P301S tau (1N4R)
was mixed with purified scFvs at the indicated concentrations and incubated for 30 min at room temperature in the
dark. 100 µl of this mix was added to each well (technical
duplicates or triplicates for each treatment), and cells were
incubated for 24 h before being trypsinized and resuspended
in flow buffer (1× HBSS with 1% FBS and 1 mM EDTA).
The rate of tau uptake was analyzed on a MACSQuant VYB
flow cytometer (20,000 cells per well analyzed for N2a cells;
full well analyzed for primary cortical neurons). Data analysis
was performed with FlowJo Version 10 and analyzed as relative fluorescence units.
Online supplemental material
Fig. S1 (A–C) shows immunoblots revealing expression of
the scFvs in cortex lysates of all 9-mo-old P301S-tg mice
analyzed in the study; Fig. S1 (D and E) shows that unbound
scFvs as well as scFv-tau complexes exist in these lysates as
measured by ELISA. Fig. S2 depicts correlation analysis between hippocampal AT8-staining and htau levels in RAB,
RIPA, and FA fractions, demonstrating a correlation for levels
of AT8 with total htau levels in RAB and FA fractions, but
not RIPA fractions. Fig. S3 A shows ELISA measurements
of htau levels in ISF with no significant differences between
control-treated and SC1 scFv– or SC3 scFv–treated mice. Fig.
S3 (B and C) depicts correlation analysis between htau levels
in CSF and ISF of young mice, showing a significant correlation in treated but not control mice. Fig. S3 D shows an
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immunoblot of coprecipitation experiments from ISF samples, revealing extracellular tau-scFv complexes. Fig. S3 (E
and F) shows tau uptake assays with N2a neuroblastoma cells
and primary cortical neuronal cultures, demonstrating significantly lower tau uptake in the presence of either SC1 or SC3
scFvs. Fig. S3 G depicts data from a seeding assay, showing that
immunodepletion with SC1 or SC3 scFvs inhibits seeding
activity of P301S-tg brain lysates.
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Figure S1. All 9-mo-old mice express the scFvs. (A–C) Immunoblot analysis shows expression of SC1 (A; n = 14), SC3 (B; n = 16), and control (C; n =
17) scFv in cortex samples of all 9-mo-old P301S-tg mice analyzed in the study. (D) ELISA for unbound scFvs revealed similar scFv levels in hippocampal RAB
fractions (n = 14 for SC1 scFv and n = 16 for SC3 scFv). (E) ELISA for tau-scFv complexes detected complexes in hippocampal RAB fractions for all 9-mo-old
P301S-tg mice except for lysates from two AAV2/8 SC3 scFv–injected mice that were below the detection limit of the assay (n = 14 for SC1 scFv and n = 16
for SC3 scFv). All graphs represent means ± SEM.
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Figure S2. AT8 staining correlates with salt-soluble and insoluble tau levels. (A–C) Correlation analysis across all groups showed a highly significant
negative correlation between htau levels in RAB fractions and positive AT8 staining in the hippocampus (A), whereas there was a positive correlation for
htau levels in FA fractions (C) and no correlation at all for htau levels in RIPA fractions (B; n = 45 in each analysis; 9-mo-old P301S-tg mice). Dashed lines
represent 95% confidence intervals.
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Figure S3. ScFvs bind to extracellular htau and inhibit tau uptake and seeding. (A) In vivo brain microdialysis followed by ELISA showed no significant differences (measured by one-way ANOVA) of extracellular htau levels between treatment groups in young (3–4.5 mo old) P301S-tg mice despite
a trend to lower tau in SC3 scFv–treated mice (n = 9 for control scFv, n = 7 for SC1 scFv, and n = 8 for SC3 scFv; ISF collected at a flow rate of 1 µl/min).
(B) Analysis of SC1 scFv– and SC3 scFv–treated mice showed a significant correlation between CSF and ISF htau levels in young P301S-tg mice (n = 6 for
SC1 scFv and n = 8 for SC3 scFv). (C) No correlation between CSF and ISF htau levels was observed in young control scFv–treated P301S-tg mice (n = 8 for
control scFv). (D) Coimmunoprecipitation from ISF samples (collected at a flow rate of 0.5 µl/min) with the anti-tau antibody HJ8.7 revealed coprecipitation
of SC3 scFv with tau when analyzed by immunoblot. As a control, ISF sample buffer was mixed with the same concentration of purified SC3 scFv (n = 3).
(E) Fluorescently labeled tau uptake by N2a cells measured by flow cytometry revealed the potential of SC1 and SC3 scFv to block cellular uptake (n = 7).
(F) Fluorescently labeled tau uptake by primary cortical neuronal cultures measured by flow cytometry showed a significant inhibition of tau uptake in
the presence of SC1 or SC3 scFvs (n = 4). (G) Immunodepletion with SC1 or SC3 scFvs inhibits seeding activity of P301S-tg brain lysate when analyzed by
measuring the FRET signal in the biosensor cells (n = 3). Dashed lines in B and C represent 95% confidence intervals. All graphs are means ± SEM. A and
E–G were analyzed by one-way ANOVA, followed by Dunnett’s multiple comparison post hoc test comparing every column to control scFv/untreated: *, P
< 0.05; ***, P < 0.001.
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